FUNCTIONAL ANALYSIS OF NUCLEAR RECEPTOR VARIANTS
核受体变体的功能分析
基本信息
- 批准号:6650825
- 负责人:
- 金额:$ 40.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-01 至 2006-08-30
- 项目状态:已结题
- 来源:
- 关键词:androstane compound clinical research fluorescence microscopy genetic polymorphism genetically modified animals human genetic material tag human tissue laboratory mouse molecular biology information system pharmacogenetics pharmacokinetics protein isoforms protein structure function retinoid binding proteins steroid hormone receptor
项目摘要
DESCRIPTION (provided by applicant): Activation of genes in response to extracellular stimuli, pathogens, pharmaceutical administration, or environmental agents, requires a highly integrated signal transduction process that directs the transcriptional machinery to modulate the appropriate network of genes. An array of cytochrome P450 (CYP) genes, as well as other biotransformation functions, are targets of these signals. Like the CYPs, the nuclear hormone receptors (NHRs) are encoded by a superfamily of genes and largely orchestrate the responses triggered by chemical and hormonal effectors. This research proposal will focus in particular on the human constitutive androstane receptor (CAR) and the RXRalpha receptor (RXRa), NHRs that have been characterized recently to mediate the transcriptional activity of 'phenobarbital-like' inducer compounds that include a variety of pharmaceuticals and xenobiotic agents. The primary hypothesis that will be tested with this program is that the CAR and RXRa nuclear receptors are genetically polymorphic and structurally variant in human populations. Furthermore, we will test the hypothesis that the respective variant receptors dictate differential biological responses. A series of 3 experimental aims are advanced to facilitate the progression of the research program through initial discovery phases to in vitro and in vivo approaches to enable biological characterization of CAR and RXRa structural variants. Investigations will include the deployment of novel knockout mouse models that enable expression of the human NHRs, and structural variants thereof, in primary hepatocytes and in liver tissues that otherwise possess null receptor backgrounds. The "humanized" mice will be analyzed for altered biological activities associated with expression of the receptor isoforms, including perturbations in response to drug exposures, aberrant receptor interactions using scanning fluorescence microscopy, and changes in the repertoire of gene expression using DNA microarray hybridizations. The presence of variant NHR receptor variants in the population likely dictates substantial interindividual differences in drug response and toxicities resulting from chemical exposures. In addition, the existence of structurally variant receptors may contribute to individual differences in the risk for human diseases, including certain cancers. The data obtained from these investigations will generate important new genetic and biological information regarding the structural diversity of prominent members of the NHR superfamily.
描述(申请人提供):基因的激活,以响应细胞外刺激,病原体,药物管理,或环境因素,需要一个高度集成的信号转导过程,指导转录机制,以调节适当的基因网络。一系列细胞色素P450(CYP)基因以及其他生物转化功能是这些信号的靶标。与Cyps一样,核激素受体(NHR)是由一个超家族基因编码的,主要协调由化学和激素效应器引发的反应。这项研究提案将特别关注人类结构性雄烷受体(CAR)和RXRpha受体(RXRA),这两种NHR最近被鉴定为介导包括各种药物和异生药物在内的“苯巴比妥类”诱导化合物的转录活性。该计划将检验的主要假设是,CAR和RXRA核受体在人类群体中具有遗传多态和结构变异。此外,我们将测试假设,各个不同的受体决定不同的生物反应。提出了一系列3个实验目标,以促进研究计划的进展,从最初的发现阶段到体外和体内方法,以实现CAR和RXRA结构变体的生物学特性。研究将包括部署新的基因敲除小鼠模型,使人类NHR及其结构变体能够在原代肝细胞和原本具有零受体背景的肝组织中表达。“人源化”的小鼠将被分析与受体亚型表达相关的改变的生物学活动,包括对药物暴露的反应的干扰,使用扫描荧光显微镜的异常受体相互作用,以及使用DNA微阵列杂交的基因表达谱的变化。人群中NHR受体变异的存在可能决定了化学暴露引起的药物反应和毒性的个体间差异。此外,结构变异受体的存在可能会导致人类疾病风险的个体差异,包括某些癌症。从这些调查中获得的数据将产生关于NHR超家族重要成员的结构多样性的重要的新的遗传和生物学信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CURTIS J OMIECINSKI其他文献
CURTIS J OMIECINSKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CURTIS J OMIECINSKI', 18)}}的其他基金
Interindividual Variability in Human Microsomal Epoxide Hydrolase
人微粒体环氧化物水解酶的个体差异
- 批准号:
7655963 - 财政年份:2009
- 资助金额:
$ 40.98万 - 项目类别:
Interindividual Variability in Human Microsomal Epoxide Hydrolase
人微粒体环氧化物水解酶的个体差异
- 批准号:
8016009 - 财政年份:2009
- 资助金额:
$ 40.98万 - 项目类别:
Interindividual Variability in Human Microsomal Epoxide Hydrolase
人微粒体环氧化物水解酶的个体差异
- 批准号:
8217302 - 财政年份:2009
- 资助金额:
$ 40.98万 - 项目类别:
Targeting Dynamics of CAR and PXR in the Mouse and Human Genomes
CAR 和 PXR 在小鼠和人类基因组中的靶向动态
- 批准号:
9021236 - 财政年份:2002
- 资助金额:
$ 40.98万 - 项目类别:
CORE--MOLECULAR BIOLOGY/BIOMARKER LABORATORY
核心--分子生物学/生物标志物实验室
- 批准号:
6577782 - 财政年份:2002
- 资助金额:
$ 40.98万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 40.98万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 40.98万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 40.98万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 40.98万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 40.98万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 40.98万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 40.98万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 40.98万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 40.98万 - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
$ 40.98万 - 项目类别: